U.S. FDA declines to approve Pfizer-OPKO growth hormone deficiency treatmentBusiness, FDA, Growth Hormone Deficiency (GHD), Not Approved, Pfizer, SharesPfizer Inc. said on January 21 the U.S. health regulator declined to approve somatrogon as a treatment for growth hormone deficiency in children that the company developed with partner Opko Health Inc. Read more January 21, 2022/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2021/06/U.S.-FDA-declines-to-approve-Avenues-non-opioid-painkiller-again-shares-drop-Reuters-6-14-21.jpg 503 960 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2022-01-21 18:18:002022-01-21 23:09:05U.S. FDA declines to approve Pfizer-OPKO growth hormone deficiency treatment